DUBLIN–()–The “Neutropenia Biologic Drug Remedy World Market Report 2021: COVID-19 Progress and Change to 2030” report has been added to ResearchAndMarkets.com’s providing.

The worldwide neutropenia biologic drug therapy market is predicted to develop from $11.55 billion in 2020 to $12.19 billion in 2021 at a compound annual progress charge (CAGR) of 5.5%. The market is predicted to succeed in $14.45 billion in 2025 at a CAGR of 4%.

Main gamers within the neutropenia biologic drug therapy market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter Worldwide, CVS Well being Corp, Novartis, Spectrum Prescription drugs, and Companion Therapeutics.

The neutropenia biologic drug therapy market consists of gross sales of biologics used for the therapy of neutropenia and associated companies by entities (organizations, sole merchants and partnerships) that produce biologics for neutropenia therapy. Neutropenia is a scientific situation characterised by a lower in neutrophil depend within the blood, leading to the next threat of creating severe infections. A neutrophil is a kind of white blood cell, which helps in combating infections.

The most important causes of neutropenia embrace most cancers chemotherapy, infections, bone marrow issues, autoimmune issues, and the usage of particular medicine. The market consists of income generated by the corporate’s manufacturing the neutropenia biologic medicine by the gross sales of those merchandise.

The neutropenia biologic drug therapy market coated on this report is segmented by drug sort into filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, sargramostim. It is usually segmented by therapy sort into antibiotic medicine, granulocyte-colony-stimulating issue (G-CSF), antifungal medicine, others and by distribution channel into retail pharmacies, hospital pharmacies, on-line pharmacies.

The introduction of biosimilars on account of patent expiry is predicted to hamper the expansion of the neutropenia biologic drug therapy market. Biosimilar is a therapeutic agent, which has excessive similarity with the unique organic product in motion however is accessible at a decrease price than the price of the unique product. Biosimilars are largely priced at 70% of the branded drug value and are more likely to substitute costly branded medicine. These inexpensive alternate options improve competitors within the biologics market placing downward strain on pricing and market worth progress.

The rise within the variety of most cancers circumstances throughout the globe is more likely to contribute to the expansion of the neutropenia biologic medicine market. On account of a rising most cancers incidence and a rise within the variety of folks choosing chemotherapy, there was an growing incidence within the variety of folks affected by neutropenia. Due to this fact, the rise in most cancers incidence charge globally is anticipated to spice up the demand for the neutropenia biologic drug therapy market over the forthcoming years.

Corporations within the neutropenia biologic drug therapy market are more and more investing in creating novel drug supply techniques to enhance the therapeutic response of the drug and improve its efficacy. Novel drug supply techniques permit the supply of a really excessive dose of medicine instantly into the neutrophils, whereas the systemic dose stays low, thus disallowing side-effects.

Key Matters Lined:

1. Govt Abstract

2. Neutropenia Biologic Drug Remedy Market Traits

3. Neutropenia Biologic Drug Remedy Market Tendencies and Methods

4. Influence Of COVID-19 On Neutropenia Biologic Drug Remedy

5. Neutropenia Biologic Drug Remedy Market Dimension and Progress

5.1. World Neutropenia Biologic Drug Remedy Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of the Market

5.1.2. Restraints On the Market

5.2. World Neutropenia Biologic Drug Remedy Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers Of the Market

5.2.2. Restraints On the Market

6. Neutropenia Biologic Drug Remedy Market Segmentation

6.1. World Neutropenia Biologic Drug Remedy Market, Segmentation by Drug Kind, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Filgrastim
  • Pegfilgrastim
  • Lenograstim
  • Lipegfilgrastim
  • Sargramostim

6.2. World Neutropenia Biologic Drug Remedy Market, Segmentation by Remedy Kind, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Antibiotic Medication
  • Granulocyte-Colony-Stimulating Issue (G-CSF)
  • Antifungal Medication
  • Others

6.3. World Neutropenia Biologic Drug Remedy Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Retail Pharmacies
  • Hospital Pharmacies
  • On-line Pharmacies

7. Neutropenia Biologic Drug Remedy Market Regional and Nation Evaluation

7.1. World Neutropenia Biologic Drug Remedy Market, Break up by Area, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. World Neutropenia Biologic Drug Remedy Market, Break up by Nation, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Corporations Talked about

  • Teva Pharmaceutical
  • Amgen
  • Sanofi
  • Mylan
  • Kyowa Kirin
  • Baxter Worldwide
  • CVS Well being Corp
  • Novartis
  • Spectrum Prescription drugs
  • Companion Therapeutics
  • Pfizer
  • Myelo Therapeutics
  • Cellerant Therapeutics
  • Sandoz (Subsidary of Novartis AG)
  • BeyondSpring Prescription drugs
  • Enzychem Lifesciences Company
  • Tianjin SinoBiotech
  • S&D Pharma SK s.r.o.
  • Generon (Shanghai) Company Ltd.
  • PhytoHealth Company
  • Dong-A ST Co.

For extra details about this report go to https://www.researchandmarkets.com/r/kf3m3b



Supply hyperlink

About Author

Leave a Reply

Leave a Reply

Your email address will not be published.

Translate »